Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153418 | 0.82 | ERN1 (0.47) | ERN1CYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL6710790 | 0.81 | ERN1 (0.54) | ERN1CYP11B1CYP11B2CYP3A4CYP2A6 | |
| SCHEMBL14841074 | 0.80 | ERN1 (0.45) | ERN1ALDH1A1 | |
| SCHEMBL11252752 | 0.80 | ERN1 (0.41) | ERN1DHODHALDH1A1 | |
| SCHEMBL894805 | 0.78 | ERN1 (0.57) | ERN1CYP11B1CYP11B2CYP3A4CYP2A6 | |
| SCHEMBL19153520 | 0.78 | NT5E (0.41) | ERN1CYP11B1CYP11B2CYP3A4ALDH1A1 | |
| SCHEMBL15624620 | 0.78 | TDO2 (0.56) | ERN1CYP11B1TDO2CYP11B2CYP3A4 | |
| SCHEMBL19153961 | 0.76 | PELI1 (0.48) | ERN1CYP3A4CYP2C9 | |
| SCHEMBL19153822 | 0.76 | ERN1 (0.43) | ERN1ALDH1A1 | |
| SCHEMBL7101000 | 0.76 | ERN1 (0.54) | ERN1CYP11B1CYP11B2CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654878-B2 | Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-19 | — | — | US | disclosed |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190031693-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-01-31 | — | — | US | disclosed |
| US-20180016288-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-01-18 | — | — | US | disclosed |
| US-20180016288-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-01-18 | — | — | US | disclosed |
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2017-08-31 | — | — | US | disclosed |
| WO-2017121969-A1 | NOVEL PHOSPHINANE AND AZAPHOSPHINANE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2017-07-20 | — | — | WO | disclosed |
| CN-104011046-B | Aminopyrimidine kinase inhibitors | 嘉世高制药公司 | 2017-05-03 | — | — | CN | disclosed |
| US-9629840-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2776432-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2015-07-23 | — | — | US | disclosed |
| US-8927525-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2776432-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | P2K DYNAMICS INC. | 2013-11-21 | — | — | US | disclosed |
| WO-2013066684-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2013-05-10 | — | — | WO | disclosed |
| CN-1694700-A | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-11-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | ERN1 638/4885CYP11B1 2712/4885TDO2 1689/4885 |
| US-10654878-B2 | Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them | TK1, AK1, PHKA1 | ERN1 411/4885CYP11B1 502/4885TDO2 2855/4885 |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | ERN1 572/4885CYP11B1 2400/4885TDO2 1431/4885 |
| US-20180016288-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TK1, AK1, PHKA1 | ERN1 411/4885CYP11B1 502/4885TDO2 2855/4885 |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | ERN1 572/4885CYP11B1 2400/4885TDO2 1431/4885 |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | PIM1, PIM2, PIM3 | ERN1 572/4885CYP11B1 2400/4885TDO2 1431/4885 |
| US-20190031693-A1 | COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AK1, TK1, PHKA1 | ERN1 402/4885CYP11B1 655/4885TDO2 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.